University of Dundee
dundee.ac.ukTotal trials
113
Active
4
Phase 3
4
Total enrollment
57,190
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 1 of 1 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Sotagliflozin | — | — | — | — | — | 1 |
Next readouts
- 2027-10-31
Top conditions
- Asthma15
- Heart Failure6
- Hepatitis C6
- Chronic Obstructive Pulmonary Disease5
- Type 1 Diabetes4
- Allergic Rhinitis4
- Left Ventricular Hypertrophy3
- Bronchiectasis Adult3
Frequently asked questions about University of Dundee
- How many clinical trials does University of Dundee have on ClinicalTrials.gov?
- University of Dundee is listed as the lead sponsor on 113 clinical trials in ClinicalTrials.gov, 4 of which are currently active (recruiting, enrolling, or ongoing).
- How many of University of Dundee's trials are in Phase 3?
- 4 of University of Dundee's trials are in Phase 3, spread across 1 active drug program.
- What therapeutic areas does University of Dundee focus on?
- University of Dundee's most-studied conditions on ClinicalTrials.gov are Asthma, Heart Failure, Hepatitis C, Chronic Obstructive Pulmonary Disease, Type 1 Diabetes.
- When are University of Dundee's next clinical trial readouts?
- University of Dundee has 1 upcoming primary-completion readout tracked here; the soonest is “Sotagliflozin in Patients With Heart Failure Symptoms and Type 1 Diabetes”, expected around 2027-10-31.